Compare Keysight Technologies Inc (KEYS) vs Mesoblast Limited (MESO) Price & Performance

Keysight Technologies (KEYS) trades at $374.66, down 1.79% on the day, with strong technical momentum indicated by bullish moving averages and a consensus price target of $416.63 representing 11.2% upside. The company demonstrates robust fundamentals with Q2 2026 EPS of $3.07 beating expectations by 24%, supported by 56% order growth driven by AI infrastructure demand and 6G development opportunities. Revenue recovery to $5.38B in 2025 and net income margin expansion to 19.14% reflect improving operational efficiency.

KEYS presents compelling growth prospects from AI and 6G tailwinds, though elevated valuation multiples (P/E 50.7) and supply chain constraints pose near-term risks. Wall Street maintains strong bullish sentiment with 81% buy ratings, while technical indicators suggest the stock is testing key resistance at $375 with support at $370. The combination of accelerating earnings, strategic positioning in high-growth markets, and institutional confidence supports a positive medium-term outlook despite valuation concerns.

MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.

The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.